SEC Form 4 · accession 0001179110-19-001405
IMMUNOGEN INC · IMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theresa Wingrove
Officer — VP of Regulatory Affairs
Period of report
Feb 5, 2019
Accepted (ET)
Feb 6, 2019 · 9:09 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000855654
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.83 | Feb 5, 2019 | A | 58,900 | A | Feb 5, 2020 | Feb 5, 2029 | Common Stock | 58,900 | 58,900 | D |
Explanation of responses
- F1Exercisable in three equal installments over three years starting on the first year anniversary of the grant.